Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE NASDAQ:ARDX NASDAQ:BLTE NASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$90.38+2.2%$84.61$34.34▼$95.32$5.59B0.62978,273 shs1.97 million shsARDXArdelyx$6.05+3.6%$6.11$3.49▼$8.40$1.49B0.584.24 million shs9.84 million shsBLTEBelite Bio$146.12-1.5%$152.52$56.10▼$200.00$5.86B-1.24195,504 shs255,089 shsSRRKScholar Rock$47.33+0.8%$47.67$27.07▼$52.19$5.67B0.691.32 million shs3.06 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics+3.74%+6.90%+12.29%+29.09%+112.27%ARDXArdelyx+3.00%+4.10%-4.42%+6.18%+64.51%BLTEBelite Bio+7.34%+8.58%+3.81%-6.85%+153.36%SRRKScholar Rock+3.05%+6.49%-0.91%+3.19%+50.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$90.38+2.2%$84.61$34.34▼$95.32$5.59B0.62978,273 shs1.97 million shsARDXArdelyx$6.05+3.6%$6.11$3.49▼$8.40$1.49B0.584.24 million shs9.84 million shsBLTEBelite Bio$146.12-1.5%$152.52$56.10▼$200.00$5.86B-1.24195,504 shs255,089 shsSRRKScholar Rock$47.33+0.8%$47.67$27.07▼$52.19$5.67B0.691.32 million shs3.06 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics+3.74%+6.90%+12.29%+29.09%+112.27%ARDXArdelyx+3.00%+4.10%-4.42%+6.18%+64.51%BLTEBelite Bio+7.34%+8.58%+3.81%-6.85%+153.36%SRRKScholar Rock+3.05%+6.49%-0.91%+3.19%+50.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 2.74Moderate Buy$114.5626.76% UpsideARDXArdelyx 2.91Moderate Buy$15.73159.95% UpsideBLTEBelite Bio 2.63Moderate Buy$203.0038.93% UpsideSRRKScholar Rock 3.12Buy$56.0018.32% UpsideCurrent Analyst Ratings BreakdownLatest ARDX, BLTE, APGE, and SRRK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026SRRKScholar Rock Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/16/2026ARDXArdelyx LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.006/15/2026BLTEBelite Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$200.006/8/2026APGEApogee Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$82.00 ➝ $97.005/28/2026APGEApogee Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$89.005/28/2026APGEApogee Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/27/2026APGEApogee Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$83.00 ➝ $81.005/27/2026APGEApogee Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$137.005/27/2026APGEApogee Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$120.00 ➝ $135.005/26/2026BLTEBelite Bio MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$223.00 ➝ $215.005/22/2026BLTEBelite Bio Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$217.00(Data available from 6/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$13.23 per shareN/AARDXArdelyx$407.32M3.67N/AN/A$0.69 per share8.77BLTEBelite BioN/AN/AN/AN/A$20.54 per shareN/ASRRKScholar RockN/AN/AN/AN/A$2.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$255.84M-$4.33N/AN/AN/AN/A-32.64%-31.25%8/10/2026 (Estimated)ARDXArdelyx-$61.60M-$0.23N/A10.80N/A-13.58%-38.11%-11.85%8/3/2026 (Estimated)BLTEBelite Bio-$77.61M-$2.53N/A120.76N/AN/A-13.14%-12.88%8/10/2026 (Estimated)SRRKScholar Rock-$377.94M-$3.59N/AN/AN/AN/A-163.52%-96.67%8/5/2026 (Estimated)Latest ARDX, BLTE, APGE, and SRRK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BLTEBelite Bio-$0.60-$0.34+$0.26-$0.68N/AN/A5/11/2026Q1 2026APGEApogee Therapeutics-$1.0658-$1.06+$0.0058-$1.06N/AN/A5/7/2026Q1 2026SRRKScholar Rock-$0.82-$0.83-$0.01-$0.83$5.00 millionN/A4/30/2026Q1 2026ARDXArdelyx-$0.13-$0.15-$0.02-$0.15$92.78 million$94.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/AARDXArdelyxN/AN/AN/AN/AN/ABLTEBelite BioN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A32.5932.59ARDXArdelyx1.373.493.28BLTEBelite BioN/A33.7133.71SRRKScholar Rock0.718.648.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%ARDXArdelyx58.92%BLTEBelite Bio0.53%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics24.30%ARDXArdelyx5.30%BLTEBelite Bio13.29%SRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9161.90 million46.86 millionOptionableARDXArdelyx90247.03 million233.94 millionOptionableBLTEBelite Bio1040.09 million34.76 millionNot OptionableSRRKScholar Rock140119.83 million103.89 millionOptionableARDX, BLTE, APGE, and SRRK HeadlinesRecent News About These CompaniesCasdin Capital LLC Makes New Investment in Scholar Rock Holding Corporation $SRRKJune 18 at 5:44 AM | marketbeat.comArmistice Capital LLC Takes Position in Scholar Rock Holding Corporation $SRRKJune 18 at 4:05 AM | marketbeat.comGranahan Investment Management LLC Raises Stock Position in Scholar Rock Holding Corporation $SRRKJune 17 at 6:41 AM | marketbeat.comPolar Capital Holdings Plc Buys 527,929 Shares of Scholar Rock Holding Corporation $SRRKJune 17 at 5:13 AM | marketbeat.comWhy Scholar Rock’s Workforce Expansion Is Drawing Attention Across BiotechnologyJune 15 at 8:20 AM | kalkinemedia.comKFirst Turn Management LLC Buys Shares of 459,727 Scholar Rock Holding Corporation $SRRKJune 14, 2026 | marketbeat.comScholar Rock Holding Corporation $SRRK is Eventide Asset Management LLC's 9th Largest PositionJune 14, 2026 | marketbeat.comScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 12, 2026 | businesswire.comScholar Rock Holding Corporation $SRRK Shares Sold by Clearbridge Investments LLCJune 11, 2026 | marketbeat.comScholar Rock Holding Corporation (SRRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comScholar Rock Holding Corporation $SRRK Stake Lessened by TD Asset Management IncJune 9, 2026 | marketbeat.comGeode Capital Management LLC Has $89.62 Million Stake in Scholar Rock Holding Corporation $SRRKJune 8, 2026 | marketbeat.comNorges Bank Takes Position in Scholar Rock Holding Corporation $SRRKJune 6, 2026 | marketbeat.comBNP Paribas Financial Markets Has $24.43 Million Position in Scholar Rock Holding Corporation $SRRKJune 6, 2026 | marketbeat.comScholar Rock Holding Corporation (NASDAQ:SRRK) Receives Average Rating of "Buy" from BrokeragesJune 6, 2026 | marketbeat.comScholar Rock (NASDAQ:SRRK) Sets New 1-Year High - Here's WhyMay 26, 2026 | marketbeat.comScholar Rock Holding Corp.May 26, 2026 | edition.cnn.com103,191 Shares in Scholar Rock Holding Corporation $SRRK Bought by Fideuram Intesa Sanpaolo Private Banking S.P.A.May 21, 2026 | marketbeat.comScholar Rock to Present at the 2026 Jefferies Global Healthcare ConferenceMay 20, 2026 | finance.yahoo.comScholar Rock to Present at the 2026 Jefferies Global Healthcare ConferenceMay 20, 2026 | businesswire.comThree Biotechs That Are Top Takeover TargetsMay 18, 2026 | 247wallst.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARDX, BLTE, APGE, and SRRK Company DescriptionsApogee Therapeutics NASDAQ:APGE$90.38 +1.95 (+2.21%) Closing price 04:00 PM EasternExtended Trading$91.17 +0.79 (+0.87%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Ardelyx NASDAQ:ARDX$6.05 +0.21 (+3.60%) Closing price 04:00 PM EasternExtended Trading$6.03 -0.02 (-0.26%) As of 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Belite Bio NASDAQ:BLTE$146.12 -2.22 (-1.50%) Closing price 04:00 PM EasternExtended Trading$146.08 -0.04 (-0.03%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Scholar Rock NASDAQ:SRRK$47.33 +0.38 (+0.81%) Closing price 04:00 PM EasternExtended Trading$47.32 0.00 (-0.01%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
